secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2023-07-13T23:59:59+00:00
Accession:  0001437749-23-019877
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa Therapeutics regains Nasdaq compliance with minimum bid price requirement
--------------------------------------------------------------------------------

- Received Nasdaq notice on July 13, 2023 that it regained compliance with Listing Rule 5550(a)(2).
- Previously notified of deficiency on Oct 5, 2022; granted 180-day extension on April 4, 2023.
- Met requirement by maintaining closing bid price >= $1.00 for 10 consecutive trading days through July 12, 2023.
- Common stock (ATOS) will continue trading on Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000143774923019877/0001437749-23-019877-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000143774923019877/atos20230713c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-019877

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer